AIML Subsidiary NeuralCloud Signs Non-Binding Agreement with Movesense to Pilot AI-Powered ECG and Holter Reporting ELEMENT--[Back to the Newsroom]# AIML Subsidiary NeuralCloud Signs Non-Binding Agreement with Movesense to Pilot AI-Powered ECG and Holter ReportingCollaboration enables deployment of MaxYieldâ"¢ and CardioYieldâ"¢ into third-party health systems and clinic sitesThis pilot expands the Movesense collaboration to scale low-cost, AI-powered 1-lead ECG and Holter-style monitoring deploymentsTORONT ...

Engagement Supports Commercial Readiness Strategy for MaxYieldâ"¢ and CardioYieldâ"¢ in the United States TORONTO, ON / ACCESS Newswire / February 10, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that its wholly owned subsidiary, Neural Cloud Solutions Inc. ("Neural Cloud"), has entered into an agreement on February 9th, 2026 with Commission Wolf, a U.S.-based sales recruiting firm, to support the build-out of Neural Cloud's U.S. commercial ...

Core Insights - NeuralCloud Solutions Inc. has announced a strategic collaboration with Movesense Ltd to enhance cardiac monitoring solutions through the integration of wearable ECG devices and AI technology [1][2]. Group 1: Collaboration Overview - The partnership designates Movesense as a primary ECG device partner for NeuralCloud, focusing on developing bundled cardiac monitoring solutions [1]. - The collaboration aims to combine Movesense's wearable single-lead ECG sensors with NeuralCloud's AI-powered platforms, including MaxYield™, CardioYield™, and Insight360™, to improve ECG acquisition and reporting [2][4]. Group 2: Technology and Product Integration - Movesense's lightweight and programmable wearable sensors provide a flexible and cost-effective hardware foundation for ECG monitoring [3]. - The integration of Movesense's sensors with NeuralCloud's AI-driven signal processing allows for comprehensive ECG workflows that surpass traditional methods [3][4]. - Insight360™ offers customizable ECG reports through user-friendly dashboards, while CardioYield™ facilitates structured Holter-style reviews, and MaxYield™ enhances signal quality and data labeling [5]. Group 3: Market Position and Strategy - The collaboration aims to address markets traditionally served by higher-cost Holter monitoring systems, potentially offering more accessible alternatives [4]. - The partnership enhances operational and commercial flexibility, enabling faster deployment and broader market reach for combined hardware and software solutions [6]. - The collaboration reflects a strategic move to embed AI-powered cardiac intelligence into real-world workflows, strengthening the companies' market position [6].

Core Insights - NeuralCloud Solutions Inc. has entered into a non-binding Commercial Agreement with Equimetrics to integrate its AI-enhanced ECG signal-processing technology into veterinary health and elite equine performance markets [1] Group 1: Company Developments - The agreement will expand NeuralCloud's MaxYield™ and CardioYield™ platforms into Equimetrics' V-PRO Clinical Monitoring and S-PRO Sports Performance product lines [1] - This collaboration aims to enhance the veterinary and equine health sector by providing AI-driven ECG signal processing for better performance optimization and cardiac safety [1] Group 2: Market Impact - The integration of advanced ECG technology is expected to enable higher-fidelity and automated interpretation of electrocardiograms (ECG) [1]

Core Insights - The article highlights the validation of AIML's innovative neural-network method for denoising and mapping ECG signals, which supports the functionality of its products MaxYield™ and CardioYield™ [1] - This validation strengthens the company's competitive edge as it progresses in commercialization and regulatory processes [1] Company Summary - AIML has developed a novel approach utilizing neural networks for ECG signal processing, which is crucial for its product offerings [1] - The successful validation of this technology is expected to enhance the company's market position and facilitate its growth in the healthcare technology sector [1] Industry Summary - The advancements in AI and machine learning applications in healthcare, particularly in ECG signal processing, are becoming increasingly significant [1] - Companies focusing on innovative solutions in medical technology are likely to gain a competitive advantage as regulatory pathways evolve [1]

Core Insights - The Toronto Heart Centre is set to conduct a comparative evaluation of CardioYield™ to enhance Holter ECG analysis and reporting efficiency [1] - The study aims to measure time savings, throughput improvements, and analysis quality when using CardioYield™ compared to current industry-standard software [1] Clinical Workflow Impact - The evaluation will focus on the impact of CardioYield™ on clinical workflows, specifically in terms of efficiency and effectiveness in ECG analysis [1] - Key metrics for assessment include time savings and improvements in throughput and analysis quality [1]